Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.
Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.
复制标题
DOI：
10.1097/md.0000000000031980
复制
发表时间：
2022-12-16
期刊：
影响因子：
1.6
通讯作者：
Zhang, Ji Ming
中科院分区：
文献类型：
--
作者：
Chen, Jing Wen;Cao, Xiong Yue;Qi, Xun;Zhang, Ji Ming
本研究旨在探讨3种核苷类似物（NAs）对血脂水平的影响。我们回顾性地纳入了在两个中心接受NAs治疗的患者，并收集了他们在就诊点的临床资料。用统计学方法分析血脂水平的差异，并探讨高脂血症的相关因素。在这两个中心，富马酸替诺福韦阿拉那胺组(TAF)-的高胆固醇血症患病率为12/181(6.6%)，富马酸替诺福韦二氧吡酯组(TDF)-的患病率为0/158(0%)，恩替卡韦组（ETV）的患病率为13/182 (7.1%)（P = 0.003）。TAF-组高甘油三酯血症患病率为30/181 (16.6%)，TDF-组为11/158 (7.0%)，etv组为26/182 (14.3%)（P = 0.025）。TAF组（n = 181、10[6、15]个月）、TDF组（n = 158、18[7.5、45]个月）、ETV组（n = 182、24[10、60]个月）总胆固醇（TC）水平分别为4.63±0.91 mmol/L、3.86±0.61 mmol/L、4.53±0.87 mmol/L；甘油三酯（TG）水平分别为1.27±0.76 mmol/L、0.87±0.51 mmol/L和1.14±0.67 mmol/L （P < 0.001）。在多因素回归分析中，与高胆固醇血症相关的因素为年龄(校正危险风险[HR] = 1.055 [1.018-1.094]；003)和体重指数（BMI）（调整后HR = 0.817 [0.669-0.998]; P = 0.048）。与高甘油三酯血症相关的因素为：TAF组（vs. TDF组）(调整后HR = 0.405 [0.167-0.980]；045)、年龄(调整HR = 1.028 (1.002 - -1.055); P =。038年),和性(调整HR = 0.190 (0.079 - -0.456); P <措施)。在TAF（10[6,15]个月）、TDF（18[7.5, 45]个月）和ETV（24[10,60]个月）治疗的患者中，TDF组的血脂水平低于TAF组和ETV组，高脂血症的发生与年龄、性别、BMI及不同治疗方式有关。
This study aimed to explore the effects of the 3 nucleos(t)ide analogues (NAs) on lipid levels. We retrospectively included patients treated with NAs at 2 centers and collected their clinical data at their visiting points. Differences in blood lipid levels were analyzed by statistical methods, and factors related to hyperlipidemia were discussed. In these 2 centers, the prevalence rates of hypercholesterolemia were 12/181 (6.6%) for tenofovir alafenamide fumarate (TAF)-, 0/158 (0%) for tenofovir disoproxil fumarate (TDF)-, and 13/182 (7.1%) for entecavir (ETV)-treated individuals (P = .003). The prevalence rates of hypertriglyceridemia were 30/181 (16.6%) for TAF-, 11/158 (7.0%) for TDF-, and 26/182 (14.3%) for ETV-treated individuals (P = .025). In TAF (n = 181, 10 [6, 15] months), TDF (n = 158, 18 [7.5, 45] months), and ETV (n = 182, 24 [10, 60] months) groups, total cholesterol (TC) levels were 4.63 ± 0.91 mmol/L, 3.86 ± 0.61 mmol/L, and 4.53 ± 0.87 mmol/L, respectively; triglyceride (TG) levels were 1.27 ± 0.76 mmol/L, 0.87 ± 0.51 mmol/L, and 1.14 ± 0.67 mmol/L, respectively (P < .001). In multivariate regression analysis, factors associated with hypercholesterolemia were age (adjusted hazard risk [HR] = 1.055 [1.018–1.094]; P = .003) and body mass index (BMI) (adjusted HR = 0.817 [0.669–0.998]; P = .048). Factors associated with hypertriglyceridemia were TAF group (vs. TDF group) (adjusted HR = 0.405 [0.167–0.980]; P = .045), age (adjusted HR = 1.028 [1.002–1.055]; P = .038), and sex (adjusted HR = 0.190 [0.079–0.456]; P < .001). Among the patients treated with TAF (10 [6, 15] months), TDF (18 [7.5, 45] months), and ETV (24 [10, 60] months), the blood lipid levels in the TDF group were lower than those in the TAF group and ETV group, and the occurrence of hyperlipidemia was associated with age, sex, BMI, and different treatment.